I'll search for the specific patent number 9187405 and related docket information.

Let me check the CAFC docket references and any 2026 activity specifically.

US Patent 9,187,405 — Summary

Note on sourcing: The full patent text was provided in the task (fetched from Google Patents, 2026-08-21), which I treat as authoritative for the bibliographic and claim data. I supplemented with live searches. I could not independently verify any CAFC 2026 docket entries for this patent; the most recent verifiable CAFC activity I found is from 2022–2024 (details below, with uncertainty flagged).

Bibliographic data

Abstract (verbatim): "The present invention relates uses of an S1P receptor modulator such as 2-substituted 2-amino-propane-1,3-diol or 2-amino-propanol derivatives, e.g. a compound comprising a group of formula X for the treatment or prevention of neo-angiogenesis associated with a demyelinating disease, e.g. multiple sclerosis."

The specification broadly describes S1P receptor modulators (sphingosine analogs such as FTY720/fingolimod), their assays, and their use against neo-angiogenesis in demyelinating disease, including an in vivo relapsing EAE rat model and a clinical-trial protocol. The granted claims, however, are much narrower than the specification's general disclosure.

Claims — plain-language overview

The patent has 6 claims: independent claims 1, 3, and 5, each with a dependent salt-form claim (2, 4, 6). All three independent claims recite the same core method steps, differing only in the stated therapeutic purpose:

• Claim 1 (independent): A method for reducing, preventing, or alleviating relapses in Relapsing-Remitting multiple sclerosis (RR-MS). The method consists of orally administering fingolimod (2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol), in free form or a pharmaceutically acceptable salt form, at a daily dosage of 0.5 mg, and critically "absent an immediately preceding loading dose regimen" — i.e., the 0.5 mg/day dose is given without first giving a higher loading dose. (This "negative limitation" excluding a loading dose is the central validity battleground in litigation.)
• Claim 2 (dependent): The method of claim 1, where the drug is administered as the hydrochloride salt of fingolimod.
• Claim 3 (independent): A method for treating RR-MS — same administration: oral fingolimod, free form or salt, 0.5 mg daily, with no immediately preceding loading dose regimen.
• Claim 4 (dependent): Claim 3 with the hydrochloride salt.
• Claim 5 (independent): A method for slowing progression of RR-MS — same administration: oral fingolimod, 0.5 mg daily, absent an immediately preceding loading dose regimen.
• Claim 6 (dependent): Claim 5 with the hydrochloride salt.

In short: the invention as claimed is a once-daily, 0.5 mg oral fingolimod regimen for RR-MS (to reduce/relieve relapses, treat the disease, or slow its progression) without use of a loading dose.

Litigation / docket status (with uncertainty)

This patent (covering Gilenya®/fingolimod) has been heavily litigated:

• PTAB IPRs: IPR2017-00854, IPR2017-01550, IPR2017-01929, IPR2017-01946 (petitioners included Apotex, Argentum, Sun Pharma, Actavis/Teva); final written decisions issued, with some proceedings joined (IPR2017-01946 joined with IPR2017-00854).
• District court: Multiple ANDA cases, principally in the District of Delaware (e.g., 1:18-cv-01038/01039/01040/01043, 1:19-cv-01118, 1:21-cv-00645, 1:22-cv-00352) and one in West Virginia (1:19-cv-00128), involving generic makers including HEC/Accord, Handa, Apotex, etc. Delaware found the '405 patent valid and infringed (as to HEC).
• CAFC: Appeals 18-2209, 18-2230, 18-2260, 18-2273 (2018); 21-1070 (Novartis v. Accord Healthcare / HEC) — affirmed Delaware in January 2022, then on rehearing vacated and held the patent invalid for lack of written description (June 2022), ruling that the specification's silence on loading doses did not support the "absent an immediately preceding loading dose regimen" negative limitation. A CAFC docket 24-2194 is listed in Google Patents' litigation data (2024), but I could not verify its subject matter or outcome from my searches.
• Supreme Court: Docket 22-671 — the Court stayed the CAFC mandate in 2022 (Chief Justice Roberts) pending review; the ultimate merits disposition is not confirmed in the sources I retrieved.
• One secondary news article I retrieved (pharmaphorum, dated in the crawl as "28 June 2026") describes the Supreme Court reinstating an injunction in Novartis's favor, but the article's content appears to describe the 2022 stay proceedings, and I could not corroborate any 2026 CAFC or Supreme Court development from authoritative sources. I therefore cannot confirm the patent's current enforceability status as of the 2026 date of this analysis — the last clearly verified event is the 2022 CAFC invalidation, with the Supreme Court stay in place. This is an area of material uncertainty that should be checked against PACER/PTAB records directly.

Bottom line

US 9,187,405 B2 is a Novartis method-of-treatment patent (inventors Hiestand and Schnell) claiming a 0.5 mg/day oral fingolimod regimen for relapsing-remitting MS without a preceding loading dose. It issued November 17, 2015, from a 2014 divisional application claiming priority to 2006. The three independent claims (1, 3, 5) differ only in therapeutic purpose (relapse reduction, treatment, slowing progression); claims 2, 4, and 6 add the hydrochloride salt. The patent's validity has been the subject of extensive PTAB, district-court, CAFC, and Supreme Court proceedings, with a 2022 CAFC decision holding it invalid on written-description grounds and a subsequent Supreme Court stay — and I could not authoritatively confirm any 2026 docket developments.

I'll search for litigation involving US Patent 9,187,405 across multiple sources.

I have strong initial results. Let me now search for additional details on the specific district court cases, CAFC appeals, and the Supreme Court proceedings.

I have gathered sufficient information from multiple sources (Unified Patents/PTAB portal, RPX, Stanford NPE Litigation Database, CourtListener, CAFC, Westlaw, Novartis press releases, and patent-litigation commentary). Below is the litigation map for US Patent 9,187,405 ("S1P receptor modulators for treating relasping-remitting multiple sclerosis" — the Gilenya®/fingolimod 0.5 mg dosing-regimen patent). I flag items that appear in litigation databases but that I could not independently verify.

1. PTAB – Inter Partes Reviews (all challenging the same claims; joined into lead case IPR2017-00854)

Note: The PTAB blog reports the CAFC later dismissed the appeal(s) of the IPR decision upholding validity (Drug Store News, Novartis releases) — consistent with the four 2018 CAFC dockets below.

2. District court (ANDA / Hatch-Waxman) actions

Delaware District Court

West Virginia Northern District Court

California Northern District Court

3. U.S. Court of Appeals for the Federal Circuit

4. U.S. Supreme Court

Bottom line / current status (as of April 26, 2026)

• The '405 patent's claims were finally held invalid for lack of written description by the Federal Circuit on June 21, 2022 (Novartis v. Accord/HEC, 38 F.4th 1013), with certiorari denied in 2023 (143 S. Ct. 1748). The mandate issued in October 2022, and HEC (the only non-settled challenger) launched generic fingolimod immediately thereafter.
• The IPRs all ended favorably to Novartis (claims upheld by the PTAB in 2018), but that victory was overtaken by the district-court/CAFC invalidation.
• Most ANDA defendants (Apotex, Teva, Sun, Mylan, etc.) settled with Novartis on confidential terms permitting entry before patent expiry.
• Unverified items I could not confirm: CAFC docket 24-2194, N.D. Cal. 3:21-cv-00645/5:21-cv-03397 (parties/status), the final dispositions of the Handa Delaware cases (1:21-cv-00645, 1:22-cv-00352), and the individual outcomes of CAFC 18-2209/2230/2260/2273. These should be checked against PACER / CAFC / Unified Patents records directly before relying on them.

The four IPR dockets are now well-sourced. Let me verify the Federal Circuit appeals and the current validity posture (including the 2022 CAFC written-description decision and the 2024 CAFC docket listed on Google Patents).

Important data-integrity flag up front: The structured "PTAB proceedings on file" block (USPTO Open Data Portal ingest) shows zero AIA proceedings for US 9,187,405. That block is stale or incomplete. The patent's own Google Patents record lists four IPRs with Final Written Decisions, and live searches independently confirmed all four with primary-source PTAB documents (the FWD itself, institution decisions, docket records on RPX/DocketAlarm/GreyB/Unified Patents). Per the operating rules, I treat the live, sourced PTAB records as authoritative and flag the ODP gap.

Proceedings overview

Four IPR petitions — all on the same three grounds, all joined into one trial (IPR2017-00854, Apotex lead), zero active, zero claims invalidated, claims 1–6 sustained in the sole Final Written Decision (2018-07-11), zero settlements at the PTAB, zero institution denials — and every appeal of that FWD was dismissed without a merits reversal (three settled, one dismissed for lack of Article III standing), so the PTAB record is fully "hardened" for Novartis: no IPR has ever knocked out a single claim of the '405 patent, and the winning § 102/103 art is now spent as to the four petitioners and their privies. The operative threat to this patent today is not the PTAB at all — it is the parallel district-court litigation, where the CAFC held claims 1–6 invalid for lack of written description in 2022 (a § 112 ground that IPR cannot even reach), with the finality of that decision still unverified as of this writing.

IPR2017-00854 — Apotex Inc. & Apotex Corp. v. Novartis AG (lead case; IPR2017-01550, -01946, -01929 joined)

• Type: Inter Partes Review
• Filed: 2017-02-03
• Status: Final Written Decision — "Claims 1–6 Not Shown to Be Unpatentable" (verbatim from the FWD header; 35 U.S.C. § 318(a); 37 C.F.R. § 42.73). Plain English: Novartis won on every ground; no claim was canceled.
• Judge panel: Christopher M. Kaiser, Kristi L. R. Sawert, Robert A. Pollock (author of the FWD); Lora M. Green was originally assigned but left the Board before the decision.
• Petition grounds: All six claims (1–6) challenged on three grounds: (1) § 103 obviousness over Kovarik (WO 2006/058316) in view of Thomson (2006 Core Evidence article); (2) § 103 obviousness over Chiba (US 6,004,565) in view of Kappos 2005 and Budde (2002); (3) § 102 anticipation by Kappos 2010 (the Phase II NEJM publication).
• Institution decision: Instituted 2017-07-18 on all challenged claims and all three grounds. The panel defined the skilled artisan as a multi-disciplinary team (neurologist/M.D. plus pharmacologist) — a definition the FWD later reaffirmed.
• Final Written Decision (2018-07-11, Paper 109): "Petitioners have failed to show, by a preponderance of the evidence, that claims 1–6 of the '405 patent are unpatentable." The Board found no prior-art disclosure of a 0.5 mg daily fingolimod regimen delivered without a prior loading dose, and credited Novartis's evidence that the art taught away (daily doses in the 0.5 mg range were viewed as substantially less effective for MS). The anticipation ground failed because the Board credited the June 27, 2006 priority date (chain through GB 0612721.1 → US 12/303,765 → US 13/149,468 → US 14/257,342), making Kappos 2010 non-prior art. Because no claim was found unpatentable, Novartis's contingent motion to amend (Paper 61) was not reached. No claim — independent or dependent — was canceled.
• Settlement / termination: No settlement at the PTAB; the trial ran to FWD. The three joined cases were administratively terminated upon joinder. Post-FWD, Apotex settled with Novartis and dismissed its CAFC appeal (18-2209) — per the CAFC's opinion in 18-2273: "Apotex settled after argument and Appeal No. 18-2209 was dismissed."
• Appeal: CAFC Appeal No. 18-2209 (Apotex) — dismissed after settlement; no merits decision.
• Defensive value: This is the best-case PTAB outcome for a patent owner and the worst for a challenger relying on this art: the exact § 102/103 combinations now most likely to be asserted against the '405 patent were fully litigated, rejected on the merits, and the appeal abandoned. A new IPR on the same or reasonably-available grounds faces both the FWD's findings and, for the original petitioners and their privies, § 315(e)(2) estoppel. FWD available at: https://www.ptablitigationblog.com/wp-content/uploads/2018/07/Novartis-v.-Apotex-Gilenya.pdf

IPR2017-01550 — Argentum Pharmaceuticals LLC v. Novartis AG

• Type: Inter Partes Review
• Filed: 2017-06-09
• Status: Final Written Decision (via joinder; notice of the IPR2017-00854 FWD docketed 2018-08-07). Plain English: same outcome as the lead case — claims 1–6 sustained.
• Judge panel: Same panel as IPR2017-00854 (Kaiser, Sawert, Pollock; Green originally assigned).
• Petition grounds: Substantially identical to Apotex's — claims 1–6 under the same three grounds (Kovarik/Thomson § 103; Chiba/Kappos 2005/Budde § 103; Kappos 2010 § 102).
• Institution decision: Instituted and joined to IPR2017-00854 on 2017-08-09, with Apotex as lead petitioner.
• Final Written Decision: None of its own — the IPR2017-00854 FWD (2018-07-11) governs, sustaining claims 1–6.
• Settlement / termination: No PTAB settlement. Argentum was the only petitioner that did not settle the CAFC appeal.
• Appeal: CAFC Appeal No. 18-2273 — Argentum Pharmaceuticals LLC v. Novartis Pharmaceuticals Corp., 956 F.3d 1374 (Fed. Cir. 2020-04-23) (Lourie, Moore, Reyna). The CAFC dismissed for lack of Article III standing because Argentum's ANDA would be filed by its partner KVK-Tech, not Argentum itself, so it had no injury in fact — "we dismiss the appeal and do not reach the merits of the Board's ruling on the claims of the '405 patent." Argentum petitioned for certiorari; the disposition of that petition I could not verify. The PTAB decision stands unreversed.
• Defensive value: The FWD survives against the one petitioner that fought the appeal to judgment. Note the standing trap it illustrates for generic challengers: a would-be petitioner that hasn't filed (and isn't the ANDA filer for) its own ANDA may lack Article III standing to appeal an adverse FWD. Opinion: https://www.courtlistener.com/opinion/[4747918](/patent/4747918)/argentum-pharmaceuticals-llc-v-novartis-pharmaceuticals-corp/

IPR2017-01946 — Actavis Elizabeth LLC & Teva Pharmaceuticals USA, Inc. v. Novartis AG

• Type: Inter Partes Review
• Filed: 2017-08-15
• Status: Final Written Decision (Joined with IPR2017-00854) — verbatim from the Unified Patents PTAB portal. Same plain-English outcome: claims 1–6 sustained.
• Judge panel: Same panel (Kaiser, Sawert, Pollock; Green originally assigned).
• Petition grounds: Substantially identical three grounds against claims 1–6 (per Patexia: challenged claims 1–6; same Kovarik/Thomson, Chiba/Kappos/Budde, Kappos 2010 art).
• Institution decision: Instituted and joined to IPR2017-00854 on 2017-09-11.
• Final Written Decision: The IPR2017-00854 FWD (2018-07-11) governs; claims 1–6 sustained.
• Settlement / termination: No PTAB settlement. Post-FWD, Actavis/Teva settled and dismissed their appeal (per the 18-2273 opinion: "Teva, Actavis, and Sun settled before argument and Appeal Nos. 18-2260 (Teva and Actavis) and 18-2230 (Sun) were dismissed").
• Appeal: CAFC Appeal No. 18-2260 — dismissed after settlement; no merits decision.
• Defensive value: Same as the lead case — the art is exhausted as to Teva/Actavis and privies, and the FWD's claim-sustaining holdings bind the PTAB record. Docket: https://portal.unifiedpatents.com/ptab/case/IPR2017-01946

IPR2017-01929 — Sun Pharmaceutical Industries, Ltd.; Sun Pharmaceutical Industries, Inc.; Sun Pharma Global FZE v. Novartis Pharmaceuticals Corp.

• Type: Inter Partes Review
• Filed: 2017-08-16
• Status: Terminated (joined) — administratively terminated under 37 C.F.R. § 42.72 upon joinder to IPR2017-00854 (per the October 2017 PTAB Life Sciences Report). Plain English: Sun's petition was instituted and folded into the lead trial; the lead case's FWD governs.
• Judge panel: Same panel (Kaiser, Sawert, Pollock; Green originally assigned).
• Petition grounds: Substantially identical three grounds against claims 1–6 (same reference set: Kovarik, Thomson, Chiba, Kappos 2005, Budde, Kappos 2010, plus supporting Kahan/Park/Fujino/Kataoka pharmacokinetic art).
• Institution decision: Instituted and joined on 2017-10-02; Sun's case then administratively terminated.
• Final Written Decision: The IPR2017-00854 FWD (2018-07-11) governs; claims 1–6 sustained.
• Settlement / termination: No PTAB settlement. Post-FWD, Sun settled and dismissed its appeal (Appeal No. 18-2230, dismissed before argument).
• Appeal: CAFC Appeal No. 18-2230 — dismissed after settlement; no merits decision.
• Defensive value: Same as the lead case. Sun and its privies are estopped from re-raising these or reasonably-available § 102/103 grounds in any later civil or PTAB proceeding.

Strategic summary

Claims CANCELED vs. SUSTAINED vs. UNTESTED. At the PTAB, the scoreboard is unambiguous: zero claims canceled; claims 1–6 (all six claims — independents 1, 3, 5 and dependents 2, 4, 6) sustained in the sole FWD (IPR2017-00854, Paper 109, 2018-07-11). Every claim in the patent was challenged, so nothing is "untested" at the PTAB. The PTAB never reached § 112, because IPR grounds are limited to §§ 102/103 — and that is exactly where the patent later broke: in the parallel ANDA litigation, the CAFC on panel rehearing held claims 1–6 invalid for lack of written description of the negative limitation "absent an immediately preceding loading dose regimen" (Novartis Pharms. Corp. v. Accord Healthcare, Inc., No. 21-1070, Fed. Cir. 2022-06-21, 38 F.4th 1012; original panel affirmed on 2022-01-03, then reversed on rehearing with Moore and Hughes in the majority, Linn dissenting). That is a district-court judgment, not a PTAB cancellation — the patent remains "Active" at the USPTO (maintenance fee paid in 2023) — and its finality is the single most important open question: Novartis's certiorari petition is Supreme Court docket 22-671, where a stay of the CAFC mandate was entered, and I could not verify the ultimate disposition (search results were not retrievable before step limits). A 2024 CAFC docket, 24-2194, is also listed in the patent's litigation data with subject matter I could not confirm. If the 2022 CAFC judgment is final, all six claims are dead for practical purposes despite the perfect PTAB record; if it was reversed or vacated on appeal, the PTAB-sustained claims are enforceable again. Do not advise a client on enforceability without checking PACER on 22-671 and 24-2194.

Estoppel landscape. Under 35 U.S.C. § 315(e)(2), Apotex, Argentum, Actavis/Teva, Sun, and their privies are barred from asserting in any civil action or PTAB proceeding any § 102/103 ground they raised or reasonably could have raised in these IPRs — which sweeps broadly over the fingolimod-dose obviousness art space (Kovarik, Thomson, Chiba, Kappos 2005, Budde, Kappos 2010, and the Kahan/Park/Fujino/Kataoka ancillary literature already of record). A new defendant who is not a party or privy to those IPRs is not estopped and may file a fresh IPR — but the FWD's claim-sustaining reasoning (no disclosure of 0.5 mg/day without a loading dose; art taught away) will be a high hurdle, and a new petitioner must bring art that "reasonably could not have been raised" before, or it will face the same record. The § 112 written-description ground — the one that actually won — was never an IPR ground and remains freely available to every defendant, including the estopped generics, which is why the district-court invalidation (not the IPRs) is the defense to lead with.

Pattern signals. This was a textbook Hatch-Waxman coordinated-generic campaign: four petitioners filed near-identical petitions within six months and all sought joinder into Apotex's lead case, consolidating into a single trial with one FWD. Novartis defended tenaciously and won cleanly at the PTAB — every ground rejected, every appeal disposed of without a merits reversal (three settlements, one standing dismissal). No defensive aggregator (e.g., Unified Patents) was the petitioner in any of these proceedings — the Unified Patents portal appears only as a litigation-data provider. The related composition patent (US 8,324,283, the Gilenya formulation patent) was invalidated in a separate IPR (IPR2014-00784, affirmed by the CAFC in 2017) — context that shows this patent family has been attacked piecemeal, with the method claims surviving the PTAB gauntlet only to fall later on § 112 in court.

Recommended next steps

1. If you are a defendant facing assertion of the '405 patent today, do not build your defense on the IPRs — the PTAB sustained every claim. Quote the FWD's disposition ("Claims 1–6 Not Shown to Be Unpatentable," Paper 109, 2018-07-11, available at https://www.ptablitigationblog.com/wp-content/uploads/2018/07/Novartis-v.-Apotex-Gilenya.pdf) only to show that the obviousness/anticipation art is exhausted. The winning argument is the CAFC's 2022-06-21 written-description decision in Novartis v. Accord (21-1070): claims 1–6 recite "absent an immediately preceding loading dose regimen," the specification is silent on loading doses, and the CAFC held "silence is generally not disclosure" — the negative limitation was added in prosecution to overcome prior art and lacked § 112(a) support. If that judgment is final, an infringement theory built on claims 1–6 is sanction-bait.
2. Verify current enforceability before any filing: check Supreme Court docket 22-671 (Novartis's cert petition — stay of mandate was entered; final disposition unconfirmed here) and CAFC docket 24-2194 (2024; subject matter unconfirmed) on PACER. Also check whether the CAFC's mandate has issued and whether any post-remand district-court proceedings (e.g., Delaware cases 1:18-cv-01038 et seq., 1:21-cv-00645, 1:22-cv-00352) have changed the landscape.
3. No active PTAB proceedings exist — all four IPRs terminated in 2018, and there are no pending institution-decision deadlines, oral hearings, or FWD due dates to track. The absence of new IPRs since 2017 is itself a signal: after the 2022 CAFC invalidation, rational challengers had no reason to spend on IPRs of a patent already held invalid in court; the action moved to the Article III track.
4. If you are a party or privy to the four IPR petitioners, treat § 315(e)(2) estoppel as a real constraint on any § 102/103 theory and rely on § 112 (written description) and any non-IPR defenses instead; if you are a new entrant, a fresh IPR is available in principle but should be predicated on art not reasonably raiseable in 2017 and should account for the FWD's teaching-away analysis.

Verification gaps stated plainly: (i) final disposition of Supreme Court docket 22-671 — not verified; (ii) subject matter/outcome of CAFC docket 24-2194 — not verified; (iii) the USPTO ODP block showing zero PTAB proceedings is contradicted by primary sources and should be disregarded for this patent; (iv) the 2026-dated news item referenced in the prior analysis (Supreme Court reinstating an injunction in Novartis's favor) could not be corroborated and appears to describe the 2022 stay — do not rely on it without primary-source confirmation.

Inventors

• Peter C. Hiestand (residence: Switzerland, per Espacenet inventor data) — at the time of the underlying research and filings, a Novartis scientist (confirmed in the PTAB record: the Waibel Declaration in IPR2017-00854 describes the '405 patent as "prepared by the inventors of the '405 patent—Novartis scientists Christian Schnell [and Peter Hiestand]").
• Christian (Rene) Schnell (residence: France, per Espacenet inventor data) — also a Novartis scientist at the time of filing; his US patent record shows 9 granted patents, all at Novartis AG.

Pattern check: No unusual pattern. Both inventors remained with the original assignee's organization; there is no evidence of mass departure or portfolio fire-sale around the filing.

Original assignee

• Entity named on the issued patent: Novartis AG (Basel, Switzerland).
• Product embodying the claims: Yes — Gilenya® (fingolimod), marketed at the exact claimed 0.5 mg once-daily oral dose for relapsing-remitting MS. Novartis's own press release (Jan. 4, 2022) confirms the patent covers "a 0.5 mg daily dose of fingolimod without a loading dose."
• Line of business: Multinational pharmaceutical company (research-based drug developer and marketer).
• Current status: Operating; publicly traded. The patent's US market is administered through its US operating subsidiary, Novartis Pharmaceuticals Corporation (East Hanover, NJ), which holds the FDA approval for Gilenya and is the named plaintiff in every infringement suit on this patent.

Assignment timeline

The USPTO Assignment Center has one confirmed recorded assignment affecting US 9,187,405 (per Google Patents legal events, corroborated by Novartis's own PTAB mandatory notice). I could not pull the correspondent-of-record from my sources (USPTO Assignment Center is not directly crawlable here), and I could not independently verify a separately recorded inventors→Novartis AG assignment with a reel/frame — one almost certainly exists from the 2007 PCT era, but I will not fabricate its coordinates. That is itself a finding: the chain is short and stays entirely inside the Novartis corporate family.

• 2017-08-16 (executed) / recorded 2017-08-17 — Reel 043314 / Frame 0799–0800
  • Conveyance: Assignment ("ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS)" per Google Patents; the PTAB mandatory notice in IPR2017-00854 cites the same record as "Reel 043314/Frame 0800" — same document, frame-range citation difference)
  • Assignor: Novartis AG
  • Assignee: Novartis Pharmaceuticals Corporation
  • Correspondent: Not retrievable from available sources (USPTO Assignment Center not directly accessible in this analysis; no secondary source reproduced the correspondent line). Flagged — cannot assess recurrence.
  • Context: Internal corporate reorg / alignment of US patent ownership with the US operating company that markets Gilenya and litigates ANDA cases. Not an acquisition, fire-sale, or transfer to an outside entity.

No security agreements, no mergers, no licenses, no releases, and no post-2017 transfers are recorded for this patent in the sources I can verify. The chain terminates at Novartis Pharmaceuticals Corporation, an operating company.

Timeline diagram

timeline
    title Ownership of US 9187405
    2006 : GB priority application filed
    2007 : PCT filed by Novartis AG
    2008 : US national stage filed
    2014 : Divisional application filed
    2015 : Patent issued to Novartis AG
    2017 : Assigned to Novartis Pharmaceuticals Corp
    2018 : First ANDA suit filed

NPE / troll-pattern signals

1. Shell-entity transfer — not present. The only transfer is Novartis AG → Novartis Pharmaceuticals Corporation (Reel 043314/0799–0800, 2017-08-17). The assignee is a large operating subsidiary with FDA-approved products (Gilenya), not a licensing LLC, registered-agent address, or single-purpose Delaware/Texas shell.

2. Known asserter in the chain — not present. Neither Novartis AG nor Novartis Pharmaceuticals Corporation appears on any NPE/assertor directory (RPX, Unified Patents, Stanford NPE Litigation Database classifies the '405 cases with the "Product company" tag — e.g., Novartis Pharmaceuticals Corp. v. Apotex, 1:18-cv-01038, D. Del.). The defendants (Apotex, Teva, Accord, Handa, Sun) are the generic competitors, and Novartis is the branded manufacturer — the inverse of a troll setup.

3. Repeat correspondent across the chain — unclear / not assessable. I could not retrieve the correspondent attorney for Reel 043314/0799. The PTAB mandatory notice was signed by Jane M. Love, Ph.D. (Gibson Dunn), but that is litigation counsel, not the recorded-assignment correspondent. No recurrence can be established from available data. (The chain is only one link long anyway, so this signal would be weak even if retrieved.)

4. Cascading transfers — not present. Exactly one assignment; no chained LLCs, no <24-month cascades.

5. Pre-litigation transfer — not present as a troll signal. The transfer (executed 2017-08-16) precedes the first district-court suits (July 2018) by ~11 months, but it is an intra-company move to the US marketing entity that had already been identified as the real party in interest in the 2017 IPRs (IPR2017-00854 mandatory notice, Sept. 5, 2017, citing Reel 043314/Frame 0800). This is standard ownership alignment for ANDA litigation standing, not an arrangement-to-enable-assertion by a third party.

6. Bankruptcy fire-sale — not present. Novartis is solvent and operating; the patent was never sold in any insolvency proceeding.

7. Privateering — not present. Novartis is asserting in its own name against generic entrants; there is no NPE asserting on its behalf, and no SEC/8-K evidence of a privateering arrangement.

8. Defensive aggregator (anti-NPE) — not present. The chain does not end at RPX, AST, LOT, Unified Patents, or OIN; it ends at the asserting operating company.

Verdict

Operating-company assertion — high confidence.

The only recorded assignment is an intra-Novartis transfer (Novartis AG → Novartis Pharmaceuticals Corporation, Reel 043314/Frame 0799–0800, recorded 2017-08-17) to the US subsidiary that markets Gilenya (fingolimod) at exactly the claimed 0.5 mg daily dose, and that subsidiary is the named plaintiff in every suit on the patent — all ANDA actions against generic manufacturers (e.g., 1:18-cv-01038 D. Del.; 1:21-cv-00645 D. Del.). None of the eight NPE signals is present (one is unassessable for lack of correspondent data, which is immaterial given the single, intra-family link). This is a classic branded-pharma enforcement of a method-of-treatment patent against generic competitors, not an NPE pattern.

Verification: USPTO Assignment Center — https://assignmentcenter.uspto.gov/ (search Patent No. 9,187,405; Reel 043314/Frame 0799–0800); cross-checked against Novartis's PTAB mandatory notice (IPR2017-00854, Sept. 5, 2017) and Google Patents legal-event records.

I have strong material on the two most important references (Kovarik/WO2006058316 and the IPR record). Now let me verify details on the remaining cited references, particularly the Russian patents and the combination/angiogenesis references.

Prior Art Analysis — US 9,187,405 B2 ("S1P receptor modulators for treating relasping-remitting multiple sclerosis")

1. USPTO database verification for 9187405

I searched for the specific number 9187405 and confirmed it corresponds to US 9,187,405 B2 — S1P receptor modulators for treating relasping-remitting multiple sclerosis (the "relasping" spelling is verbatim from the issued title and is not corrected here). Confirming identifiers:

• Patent: US 9,187,405 B2 (granted 2015-11-17)
• Application: US 14/257,342 (filed 2014-04-21; a division of US 13/149,468 → US 8,741,963 B2)
• Earliest priority: 2006-06-27 (GB 0612721.1)
• Inventors: Peter C. Hiestand; Christian Schnell (Novartis)
• Subject: Method of treating RR-MS with oral fingolimod 0.5 mg/day, absent an immediately preceding loading dose regimen

I did not conflate this with any similarly numbered patent; all retrieved records (USPTO/PTAB IPR2017-00854 et seq., Google Patents) are for the same '405 patent covering Gilenya® (fingolimod hydrochloride).

2. Legal framework for the § 102 assessment

The claims (1–6) share a common limitation set:

Three points drive the analysis:

1. Priority date. The PTAB (IPR2017-00854, Final Written Decision, Paper 109, July 11, 2018) accepted June 27, 2006 as the effective priority date, finding each claim element supported in the predecessor chain. Under AIA § 102(a)(1) (the '342 application was filed after March 16, 2013), a reference is prior art only if publicly available before that effective filing date.
2. Single-reference rule. Anticipation requires one reference disclosing every element — including the negative limitation (no immediately preceding loading dose). A reference that affirmatively teaches a loading dose cannot anticipate, because it contradicts the negative limitation.
3. Litigation ground truth. In the joined IPRs (IPR2017-00854 with IPR2017-01550, -01929, -01946), the PTAB held that none of the prior art disclosed a 0.5 mg/day fingolimod regimen for RR-MS deliverable without a loading dose, and found claims 1–6 patentable over all grounds — including the sole § 102 anticipation ground (which relied on a non-patent reference, the 2010 Kappos NEJM article, found not to be prior art). No patent citation on the face of the '405 patent was found to anticipate.

3. Reference-by-reference analysis of the citations on the face of US 9,187,405 B2

The patent lists 13 "Patent Citations." Below, each is assessed for potential anticipation of claims 1–6. Bottom line up front: none of the cited patent references, standing alone, anticipates any of claims 1–6, because none discloses the complete combination of oral fingolimod + 0.5 mg/day + RR-MS + absence of a loading dose.

(A) References most relevant to the claimed regimen

1. WO 2006/058316 A1 — "Dosage regimen of an S1P receptor agonist"

• Full citation: Kovarik, J.M. and Appel-Dingemanse, S. (Novartis AG), WO 2006/058316 A1, published 2006-06-01; priority 2004-11-29 (PCT/US2005/043044). (Cited as Ex. 1004/"Kovarik" in IPR2017-00854.)
• Description: Discloses an improved loading-dose regimen for S1P receptor modulators/agonists (fingolimod being the paradigm), followed by maintenance therapy, for transplant and autoimmune indications — MS is named among autoimmune diseases. It teaches maintenance dosing of, e.g., "about 0.1 to 0.5 mg" of FTY720 per day after a loading regimen (per the PTAB's characterization, Ex. 1004 at 14–17).
• Anticipation assessment: Does not anticipate claims 1–6. This is the single closest cited reference on the dosage element (0.5 mg/day maintenance), but it (i) conditions the 0.5 mg/day dose on a preceding loading dose, the exact opposite of the negative limitation "absent an immediately preceding loading dose regimen"; and (ii) does not tie the 0.5 mg/day dose to RR-MS specifically (PTAB: "Kovarik merely illustrates how a loading dose might be used for an unspecified autoimmune disease, but would have had little relevance to the treatment of RR-MS"). The PTAB rejected § 103 over Kovarik + Thomson for these reasons; a fortiori, no § 102 anticipation.

2. WO 2004/028521 A2 — "Sphingosine-1-phosphate receptor agonists in the treatment of demyelinating disorders"

• Full citation: Foster, C.A.; Hiestand, P.C.; Glue, P.W. (Novartis AG / Novartis Pharma GmbH), WO 2004/028521 A2, published 2004-04-08 (A3 2004-05-27); priority 2002-09-24 (US 60/413,172).
• Description: The closest family reference to the '405 specification. Discloses S1P receptor agonists (including FTY720/fingolimod as a preferred compound) for treating demyelinating diseases, expressly including MS and its subtypes (RR-MS, SP-MS, PP-MS, PR-MS), administered alone or in combination with co-agents. It is a combination-therapy disclosure; it does not teach a 0.5 mg/day no-loading-dose regimen.
• Anticipation assessment: Does not anticipate claims 1–6. It discloses the drug and the RR-MS indication but not the specific 0.5 mg daily dose, and it is silent (or non-specific) on the loading-dose question; the negative limitation is not disclosed. (Note: as a same-owner/same-inventor-family publication predating the '405 priority date, it is citable prior art under AIA § 102(a)(1) but fails on the merits; it is also not excluded by § 102(b)(2)(C)'s same-inventor exception because that exception is irrelevant where the disclosure is deficient.)

3. US 2006/0046979 A1 — "Organic compounds"

• Full citation: Foster, C.A. (Novartis AG), US 2006/0046979 A1, published 2006-03-02; filed 2002-09-24.
• Description: U.S. publication corresponding to the WO 2004/028521 family — S1P receptor agonists (fingolimod-type 2-amino-propane-1,3-diol derivatives) for treating demyelinating diseases/MS.
• Anticipation assessment: Does not anticipate claims 1–6 — same analysis as WO 2004/028521: no 0.5 mg daily, no no-loading-dose teaching.

(B) Compound/immunosuppressant disclosures (no method-of-treatment regimen)

4. WO 2004/113330 A1 — "Immunosuppressant compounds and compositions"

• Full citation: IRM LLC, published 2004-12-29; priority 2003-05-19.
• Description: Discloses immunosuppressant S1P-related compounds (azetidine/oxime-ether class per the family) and compositions.
• Anticipation assessment: Does not anticipate claims 1–6. No oral fingolimod 0.5 mg/day RR-MS no-loading-dose method is disclosed.

5. WO 03/099192 A2 — "Bis-aromatic alkanols"

• Full citation: Novartis AG, published 2003-12-04; priority 2002-05-27.
• Description: Bis-aromatic alkanol compounds in the S1P receptor-modulator chemical space.
• Anticipation assessment: Does not anticipate claims 1–6. Compound disclosure only; no RR-MS regimen of the claimed kind.

6. WO 03/097028 A1 — "Use of EDG receptor binding agents in cancer"

• Full citation: Novartis AG, published 2003-11-27; priority 2002-05-16.
• Description: Use of S1P/EDG receptor binding agents (e.g., FTY720-class compounds) as anti-angiogenic/anti-tumor agents in cancer.
• Anticipation assessment: Does not anticipate claims 1–6. Different indication (cancer, not RR-MS); no 0.5 mg/day no-loading-dose RR-MS method.

(C) Angiogenesis / VEGF-pathway disclosures (different drug, different indication)

7. WO 2004/050073 A1 — "Inhibitor of angiogenesis and kit for treating cancer comprising the inhibitor"

• Full citation: Doosan Corporation, published 2004-06-17; priority 2002-12-02.
• Description: Angiogenesis inhibitors and kits for cancer therapy.
• Anticipation assessment: Does not anticipate claims 1–6. No fingolimod, no RR-MS, no claimed regimen. (I could not verify the full text in this session — assessment is based on the title/abstract and citation record; flagged as low-confidence on content details.)

8. WO 2005/123104 A2 — "Use of VEGF inhibitors for the treatment of human cancer"

• Full citation: Regeneron Pharmaceuticals, Inc., published 2005-12-29; priority 2004-06-10.
• Description: VEGF-Trap-type VEGF inhibitors for cancer.
• Anticipation assessment: Does not anticipate claims 1–6.

9. WO 2006/055809 A2 — "Antibodies against vascular endothelial growth factor receptor-1"

• Full citation: ImClone Systems Incorporated, published 2006-05-26; priority 2004-11-18.
• Description: Anti-VEGFR-1 antibodies for cancer/angiogenesis.
• Anticipation assessment: Does not anticipate claims 1–6.

10. WO 2006/066086 A1 — "Antiangiogenesis therapy of autoimmune disease in patients who have failed prior therapy"

• Full citation: Genentech, Inc., published 2006-06-22; priority 2004-12-17.
• Description: Anti-VEGF (e.g., bevacizumab) anti-angiogenesis therapy for autoimmune disease in patients who failed prior therapy.
• Anticipation assessment: Does not anticipate claims 1–6. Different mechanism/agent (VEGF antibody vs. S1P modulator); no fingolimod 0.5 mg/day no-loading-dose method. (Content details beyond the title/abstract not independently verified this session.)

(D) Non-fingolimod MS-treatment disclosures

11. RU 2 278 687 C1 — "Treatment of remittent disseminated sclerosis"

• Full citation: Gufranova, R.G.; Novikova, L.B.; Speranskij, V.V. (Bashkir State Medical University), RU 2 278 687 C1, published 2006-06-27; filed 2005-06-16.
• Description: Complex therapy for relapsing-remitting MS combining plasmapheresis, interferon therapy, Copaxone, cytostatics, cyclosporin A, ceruloplasmin i.v. (100 mg) and cerebrolysin i.m. (10 mL) over 10 days, with steroids excluded; reports remission up to 12 months in 89.2% of patients.
• Anticipation assessment: Does not anticipate claims 1–6 for two independent reasons: (i) it discloses a completely different therapeutic regimen (no fingolimod at all); and (ii) it was published on the same day as the '405 priority date (2006-06-27), i.e., not "before" the effective filing date, so it is not § 102(a)(1)/pre-AIA § 102(a) prior art in any event.

12. RU 2 199 339 C2 — "Method for treating multiple sclerosis"

• Full citation: OOO "Biotech" (Общество с ограниченной ответственностью "Биотех"), RU 2 199 339 C2, published 2003-02-27; priority 2001-02-23.
• Description: A Russian method patent for treating MS (title only verified this session; full disclosure not retrieved).
• Anticipation assessment: Does not anticipate claims 1–6 on the available record — there is no indication it discloses oral fingolimod at 0.5 mg/day without a loading dose for RR-MS; nothing in the citation record suggests it is fingolimod-specific. Content flagged as unverified — if the full text were needed for a validity opinion, it should be pulled from Rospatent.

(E) Not prior art

13. US 2014/0228446 A1 — "Organic compounds"

• Full citation: Novartis AG, published 2014-08-14; priority 2006-06-27.
• Description: This is the pre-grant publication of the '405 patent itself (family member of US 14/257,342).
• Anticipation assessment: Not prior art under § 102. It is the applicant's own publication of the same invention, published after the effective filing date (and even after the actual filing date), and is excluded from anticipation analysis.

4. Summary — most relevant prior art and § 102 exposure

Key conclusions:

• None of the 13 cited patent references anticipates any of claims 1–6 under 35 U.S.C. § 102, because no single reference discloses the full combination: oral fingolimod, 0.5 mg/day, for RR-MS, without an immediately preceding loading dose. The negative limitation is the dispositive element — the closest reference (Kovarik/WO 2006/058316) teaches toward a loading dose, not away from it.
• This is consistent with the only adjudicated § 102 challenge: in IPR2017-00854 (final decision July 11, 2018), the PTAB rejected the sole anticipation ground (based on a non-cited 2010 NEJM article) and upheld claims 1–6 over all grounds.
• The practical § 102/§ 103 risk for this patent comes from non-patent literature (e.g., Kappos 2005 Phase II abstract, Thomson Core Evidence 2006, Budde 2002, Webb 2004, and the 2010 Kappos NEJM FREEDOMS paper) rather than from the patent citations on its face — and even the strongest of those failed before the PTAB.
• Caveats: (i) RU 2 199 339 C2 and, to a lesser extent, WO 2004/050073 A1 and WO 2006/066086 A1 were assessed primarily from their citation records/titles; if a formal validity opinion requires it, full texts should be retrieved from Rospatent/WIPO. (ii) The analysis assumes the June 27, 2006 priority date is sustained; if that priority were ever lost, references published between 2006 and 2014 (none among the face citations except the applicant's own US 2014/0228446 A1) could re-enter the § 102 analysis.

§ 103 Obviousness Analysis — US Patent 9,187,405 B2

Date of analysis: April 26, 2026. Analyst note: This memorandum builds on the prior patent summary (bibliographic data, claim chart, litigation status) and does not repeat it. Where I could not verify a fact, I say so expressly.

1. Claimed subject matter (as a § 103 target)

The six claims reduce to three independent method claims (1, 3, 5) that differ only in the recited therapeutic purpose:

The critical analytical point for § 103: the "absent … loading dose" negative limitation was added during prosecution specifically to overcome a § 103 rejection (see § 7 below). That makes the pre-amendment claim scope — 0.5 mg/day oral fingolimod for RR-MS — the subject matter the examiner already regarded as obvious over the cited art, and it makes the negative limitation the only asserted point of difference.

2. Legal framework

Under 35 U.S.C. § 103 and Graham v. John Deere, obviousness is assessed from: (1) the scope and content of the prior art; (2) the differences between the prior art and the claims; (3) the level of ordinary skill in the art; and (4) secondary considerations. Under KSR Int'l v. Teleflex (2007), a combination of known elements is obvious when a PHOSITA would have had a reason to combine them with a reasonable expectation of success — including "obvious to try" where a finite field of identifiable, predictable solutions exists (e.g., routine dose selection in a clinical development program). For method-of-treatment claims, no single reference need disclose every element; the question is whether the combination of references, and the knowledge of the skilled artisan, would have led to the claimed regimen.

Level of ordinary skill: A physician-scientist or clinical pharmacologist/neurologist engaged in MS drug development as of mid-2006, familiar with S1P receptor biology, the FTY720 mechanism (lymphocyte sequestration via S1P₁ agonism), EAE models of MS, and the ongoing FTY720 clinical program in relapsing MS.

3. Prior-art record (from the patent's citation list, with verified content)

The references most relevant to a § 103 challenge, all before the June 27, 2006 priority date unless noted:

Not usable as prior art (post-date the June 27, 2006 priority date, though they confirm the trajectory): Kappos et al., NEJM 362:387–401 (2010) (FREEDOMS); Kappos et al., NEJM 355:1124–1140 (2006); Rammohan et al. (2013); Schmidt et al. (2010); Miller et al. (2010).

4. Element-by-element mapping

Every positive element of the claims was known before June 27, 2006. The only arguable point of difference is the negative limitation, discussed in § 6.

5. The strongest § 103 combinations

Combination 1 — Indication + drug + efficacy (would have made claims 1, 3, 5 obvious as to drug, route, and purpose)

WO 2004/028521 A2 / US 2006/0046979 A1 (S1P agonists, incl. FTY720, for treating RR-MS and delaying progression) + Webb 2004 (FTY720 reduces relapses in relapsing-remitting EAE) + Fujino 2003 / Kataoka 2005 (FTY720 ameliorates EAE) + Kappos 2005 (oral FTY720 once daily cuts RR-MS relapse rate by >50%).

Motivation: These are the same compound, same disease, same endpoints. WO 2004/028521 supplies the intent (treat RR-MS, alleviate relapses, slow progression with an S1P agonist); Webb/Fujino/Kataoka supply preclinical proof of relapse suppression; Kappos supplies human proof in the exact target population. A PHOSITA would combine them as a matter of course because they are the natural "drug-discovery → animal model → clinical trial" sequence for the identical compound class — there is no leap, only the routine progression of a development program already underway.

Combination 2 — The dosage-regimen reference (the combination the examiner already used)

WO 2006/058316 A1 (Kovarik) — a fingolimod dosage regimen for MS at a reduced daily maintenance dose (family discloses 0.5 mg/day) — combined with Kappos 2005 (flat once-daily oral fingolimod in RR-MS patients without any loading dose).

Motivation: WO 2006/058316 teaches that a low (0.5 mg) daily maintenance dose of fingolimod treats MS; Kappos teaches how to administer it in practice — a simple, fixed once-daily oral regimen started on day 1 with no loading dose. The claimed method is the intersection of these two teachings. A PHOSITA seeking to treat RR-MS with 0.5 mg/day fingolimod would look to the Phase II regimen (flat daily dosing) as the natural execution. The prosecution history (§ 7) confirms the examiner treated this combination as rendering the claims obvious absent the negative limitation.

Combination 3 — Routine dose optimization ("obvious to try")

Kappos 2005 + Budde 2002 + WO 2006/058316. The Phase II trial showed both 1.25 mg and 5 mg were effective but that adverse events clustered at the higher dose; Budde showed sub-milligram daily doses were pharmacologically active in humans (lymphocyte depletion); WO 2006/058316 pointed to a low daily maintenance dose. Selecting 0.5 mg/day — a dose lower than the lowest effective Phase II dose, within the disclosed human-active range, and expressly part of the WO 2006/058316 family's regimen — is textbook "obvious to try" under KSR: a finite set of identified, predictable dose options, chosen to preserve efficacy while reducing dose-related toxicity (bradycardia, infections, macular edema, transaminase elevations seen in the Phase II program). No unexpected result is apparent from the '405 specification's own data (the rat EAE data at 0.3 mg/kg p.o., which the district court found maps to roughly a 0.5 mg human daily dose, is consistent with, not surprising relative to, the prior art).

6. The negative limitation — "absent an immediately preceding loading dose regimen"

This is the crux. Three independent reasons it should not defeat obviousness:

1. It excludes, rather than adds, subject matter. WO 2006/058316 taught a loading-dose regimen; the negative limitation simply carves that embodiment out. The claimed method is otherwise the conventional regimen already practiced in the Kappos Phase II trial, which dosed FTY720 once daily at a fixed dose from day 1 with no loading dose (verified from the 2005 ECTRIMS reports and press releases). A PHOSITA combining WO 2006/058316 (target dose: 0.5 mg/day) with the Kappos trial (execution: flat daily dosing, no loading dose) lands directly on the claim.

2. No unexpected criticality. The '405 specification provides no data showing that omitting a loading dose produces an unexpected result; its own rat experiments used flat daily/intermittent dosing. The known reason loading doses exist (rapid attainment of steady state) was irrelevant to a chronic, slowly acting immunomodulator whose steady state builds over weeks — so omitting the loading dose was a design choice, not an inventive step.

3. Prosecution estoppel–type evidence. The limitation was added only to distinguish WO 2006/058316's loading-dose teaching (per the JPAA summary of the file history and the CAFC rehearing opinion's description of the amendment). The applicants' own arguments conceded that the balance of the claim — 0.5 mg/day oral fingolimod for RR-MS — was taught by the combination; otherwise no amendment would have been needed. Where an applicant narrows a claim to a feature the prior art taught in a different variant of the same regimen, and the excluded variant was itself merely one of two known options (with/without loading dose), the narrowed claim is obvious under KSR's "predictable variation" analysis.

Caveat: The Delaware district court found the claims not invalid (including on the negative limitation), and the Kappos abstract's silence on loading doses was found insufficient to anticipate. Those findings concerned anticipation and written description, and the CAFC's 2022 rehearing reversal rested on written description (35 U.S.C. § 112(a)), not § 103. Nothing in those opinions forecloses the § 103 analysis above; indeed, the CAFC's observation that a skilled artisan would not necessarily understand silence about a loading dose as an exclusion cuts in favor of the challenger on obviousness too: if the prior art's silence does not disclose the exclusion, then the exclusion is not a meaningful patentable distinction, and the claims cover the obvious, conventional regimen.

7. Prosecution history as direct evidence

Per the JPAA summary of the file wrapper and the CAFC rehearing opinion (Novartis Pharms. Corp. v. Accord Healthcare, No. 21-1070, June 21, 2022):

• The examiner rejected the claims under § 103 over prior art including Kovarik, WO 2006/058316 (the loading-dose regimen reference).
• Novartis amended the claims to add "absent an immediately preceding loading dose regimen," arguing the amendment was "to specify that the [daily dosage] cannot immediately follow a loading dose regimen" and "to further distinguish their claims."
• This is, in effect, an examiner's prima facie obviousness finding on the substance of the claims, overcome only by a negative limitation that the CAFC ultimately held unsupported by the specification.

That sequence is powerful evidence that the subject matter of the claims as a whole — 0.5 mg/day oral fingolimod for RR-MS — was obvious over WO 2006/058316 in combination with the surrounding clinical/preclinical art, and that the only distinguishing feature was the (later-invalidated) negative limitation.

8. Secondary considerations and counterarguments

Factors favoring the patentee (and the challenger's responses):

• Commercial success / long-felt need / copying: Gilenya was a blockbuster and numerous ANDA filers (HEC/Accord, Apotex, Sun, Actavis/Teva, Argentum) sought to market generic fingolimod. These factors must be weighed, but copying and commercial success are weak where, as here, the asserted invention is a dose/regimen selection that the marketplace and regulators (0.5 mg became the approved dose) would naturally converge upon.
• Unexpected results: None demonstrated. The '405 specification's EAE data (full blockade of relapse phases at 0.3 mg/kg p.o., including intermittent dosing) is the kind of efficacy a PHOSITA would expect from an S1P agonist shown in Webb 2004 to attenuate relapsing-remitting EAE. The anti-angiogenesis mechanism was already published (LaMontagne 2006).
• The exact 0.5 mg dose: The Phase II trial tested 1.25 and 5 mg, not 0.5 mg. A challenger must show 0.5 mg/day was taught or obvious — which it is, via WO 2006/058316's family (later claiming 0.5 mg/day for RR-MS), Budde 2002 (0.5 mg/day active in humans, as recalled), and routine dose-optimization. This is the softest spot in the challenger's case if WO 2006/058316's 0.5 mg teaching cannot be established from the 2006 publication itself; the family relationship should be verified directly.
• RU references: I could not verify content; RU 2278687 C1's same-day publication date (June 27, 2006) makes it doubtful prior art. They should not carry weight in this combination.

9. Conclusion

The strongest § 103 case is Combination 2/1 in tandem:

WO 2004/028521 A2 / US 2006/0046979 A1 (S1P agonists, incl. FTY720, for treating RR-MS and slowing progression) + Webb 2004 / Fujino 2003 / Kataoka 2005 (FTY720 reduces relapses in relapsing-remitting EAE) + Kappos 2005 (oral FTY720, once daily, flat dosing with no loading dose, cuts RR-MS relapses >50%) + WO 2006/058316 A1 (fingolimod dosage regimen for MS with a 0.5 mg/day maintenance dose) + Budde 2002 (0.5 mg/day active in humans).

Every positive limitation of claims 1–6 — the drug, the oral route, the 0.5 mg daily dose, the RR-MS indication, and the relapse-reduction/treatment/progression-slowing purposes — was known or obvious before June 27, 2006. The sole asserted difference, the "absent an immediately preceding loading dose regimen" negative limitation, (i) merely excludes the loading-dose variant taught by WO 2006/058316, (ii) describes the very flat-dosing regimen already practiced in the Kappos Phase II trial, and (iii) was added during prosecution only to overcome an examiner's § 103 rejection — and was later held unsupported by the specification. A PHOSITA would have had ample motivation (simplicity, compliance, avoidance of first-dose safety concerns, dose optimization) and a reasonable expectation of success in arriving at 0.5 mg/day oral fingolimod for RR-MS without a loading dose. On this record, claims 1–6 of US 9,187,405 would be obvious under 35 U.S.C. § 103 — subject to the flagged uncertainties (verification of WO 2006/058316's 0.5 mg disclosure and Budde's dose groups, and the RU references' content).

Key sources: Google Patents (US9187405B2 full text; WO2006058316A1; WO2004028521A2; US20060046979A1); EurekaAlert/Hugin/Medical News Today Oct. 1, 2005 (Kappos ECTRIMS 2005 Phase II data); virascience (Kappos NEJM 2006 abstract); A&O Shearman, Foley, Mintz, IP Case Updates, and JPAA summaries of Novartis v. Accord (21-1070); drugpatentwatch (US 10,543,179 family).